Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Musa Hassan-King is active.

Publication


Featured researches published by Musa Hassan-King.


Clinical Infectious Diseases | 2013

Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity.

Paul A. Kristiansen; Fabien Diomandé; Absatou Ky Ba; Idrissa Sanou; Abdoul Salam Ouedraogo; Rasmata Ouédraogo; Lassana Sangaré; Denis Kandolo; Flavien Aké; Inger Marie Saga; Thomas A. Clark; Lara K. Misegades; Stacey W. Martin; Jennifer Dolan Thomas; Sylvestre Tiendrebeogo; Musa Hassan-King; Mamoudou H. Djingarey; Nancy E. Messonnier; Marie-Pierre Preziosi; F. Marc LaForce; Dominique A. Caugant

BACKGROUND The conjugate vaccine against serogroup A Neisseria meningitidis (NmA), MenAfriVac, was first introduced in mass vaccination campaigns of 1-29-year-olds in Burkina Faso in 2010. It is not known whether MenAfriVac has an impact on NmA carriage. METHODS We conducted a repeated cross-sectional meningococcal carriage study in a representative portion of the 1-29-year-old population in 3 districts in Burkina Faso before and up to 13 months after vaccination. One district was vaccinated in September 2010, and the other 2 were vaccinated in December 2010. We analyzed 25 521 oropharyngeal samples, of which 22 093 were obtained after vaccination. RESULTS In October-November 2010, NmA carriage prevalence in the unvaccinated districts was comparable to the baseline established in 2009, but absent in the vaccinated district. Serogroup X N. meningitidis (NmX) dominated in both vaccinated and unvaccinated districts. With 4 additional sampling campaigns performed throughout 2011 in the 3 districts, overall postvaccination meningococcal carriage prevalence was 6.95%, with NmX dominating but declining for each campaign (from 8.66% to 1.97%). Compared with a baseline NmA carriage prevalence of 0.39%, no NmA was identified after vaccination. Overall vaccination coverage in the population sampled was 89.7%, declining over time in 1-year-olds (from 87.1% to 26.5%), as unvaccinated infants reached 1 year of age. NmA carriage was eliminated in both the vaccinated and unvaccinated population from 3 weeks up to 13 months after mass vaccination (P = .003). CONCLUSIONS The disappearance of NmA carriage among both vaccinated and unvaccinated populations is consistent with a vaccine-induced herd immunity effect.


Clinical and Vaccine Immunology | 2011

Baseline Meningococcal Carriage in Burkina Faso before the Introduction of a Meningococcal Serogroup A Conjugate Vaccine

Paul A. Kristiansen; Fabien Diomandé; Stanley C. Wei; Rasmata Ouédraogo; Lassana Sangaré; Idrissa Sanou; Denis Kandolo; Pascal Kaboré; Thomas A. Clark; Abdoul-Salam Ouédraogo; Ki Ba Absatou; Charles D. Ouédraogo; Musa Hassan-King; Jennifer Dolan Thomas; Cynthia Hatcher; Mamoudou H. Djingarey; Nancy E. Messonnier; Marie-Pierre Preziosi; Marc LaForce; Dominique A. Caugant

ABSTRACT The serogroup A meningococcal conjugate vaccine MenAfriVac has the potential to confer herd immunity by reducing carriage prevalence of epidemic strains. To better understand this phenomenon, we initiated a meningococcal carriage study to determine the baseline carriage rate and serogroup distribution before vaccine introduction in the 1- to 29-year old population in Burkina Faso, the group chosen for the first introduction of the vaccine. A multiple cross-sectional carriage study was conducted in one urban and two rural districts in Burkina Faso in 2009. Every 3 months, oropharyngeal samples were collected from >5,000 randomly selected individuals within a 4-week period. Isolation and identification of the meningococci from 20,326 samples were performed by national laboratories in Burkina Faso. Confirmation and further strain characterization, including genogrouping, multilocus sequence typing, and porA-fetA sequencing, were performed in Norway. The overall carriage prevalence for meningococci was 3.98%; the highest prevalence was among the 15- to 19-year-olds for males and among the 10- to 14-year-olds for females. Serogroup Y dominated (2.28%), followed by serogroups X (0.44%), A (0.39%), and W135 (0.34%). Carriage prevalence was the highest in the rural districts and in the dry season, but serogroup distribution also varied by district. A total of 29 sequence types (STs) and 51 porA-fetA combinations were identified. The dominant clone was serogroup Y, ST-4375, P1.5-1,2-2/F5-8, belonging to the ST-23 complex (47%). All serogroup A isolates were ST-2859 of the ST-5 complex with P1.20,9/F3-1. This study forms a solid basis for evaluating the impact of MenAfriVac introduction on serogroup A carriage.


The Journal of Infectious Diseases | 2015

The Diversity of Meningococcal Carriage Across the African Meningitis Belt and the Impact of Vaccination With a Group A Meningococcal Conjugate Vaccine

Oumer Ali; Abraham Aseffa; Ahmed Bedru; Tsehaynesh Lema; Tesfaye Moti; Yenenesh Tekletsion; Alemayehu Worku; Haimanot Guebre Xabher; Lawrence Yamuah; Rahamatou Moustapha Boukary; Jean-Marc Collard; Ibrahim Dan Dano; Ibrahim Habiboulaye; Bassira Issaka; Jean François Jusot; Sani Ousmane; Issoufa Rabe; Doumagoum Moto Daugla; Jean Pierre Gami; Kadidja Gamougam; Lodoum Mbainadji; Nathan Naibei; Maxime Narbé; Jacques Toralta; Abdoulaye Berthe; Kanny Diallo; Mahamadou Keita; Uma Onwuchekwa; Samba O. Sow; Boubou Tamboura

Background. Study of meningococcal carriage is essential to understanding the epidemiology of Neisseria meningitidis infection. Methods. Twenty cross-sectional carriage surveys were conducted in 7 countries in the African meningitis belt; 5 surveys were conducted after introduction of a new serogroup A meningococcal conjugate vaccine (MenAfriVac). Pharyngeal swab specimens were collected, and Neisseria species were identified by microbiological and molecular techniques. Results. A total of 1687 of 48 490 participants (3.4%; 95% confidence interval [CI], 3.2%–3.6%) carried meningococci. Carriage was more frequent in individuals aged 5–14 years, relative to those aged 15–29 years (adjusted odds ratio [OR], 1.41; 95% CI, 1.25–1.60); in males, relative to females (adjusted OR, 1.17; 95% CI, 1.10–1.24); in individuals in rural areas, relative to those in urban areas (adjusted OR, 1.44; 95% CI, 1.28–1.63); and in the dry season, relative to the rainy season (adjusted OR, 1.54; 95% CI, 1.37–1.75). Forty-eight percent of isolates had genes encoding disease-associated polysaccharide capsules; genogroup W predominated, and genogroup A was rare. Strain diversity was lower in countries in the center of the meningitis belt than in Senegal or Ethiopia. The prevalence of genogroup A fell from 0.7% to 0.02% in Chad following mass vaccination with MenAfriVac. Conclusions. The prevalence of meningococcal carriage in the African meningitis belt is lower than in industrialized countries and is very diverse and dynamic, even in the absence of vaccination.


Clinical and Vaccine Immunology | 2011

Meningococcal Group C and W135 Immunological Hyporesponsiveness in African Toddlers

Helen Findlow; Samba O. Sow; Ray Borrow; Milagritos D. Tapia; Fadima Cheick Haidara; Adebayo Akinsola; Olubukola T. Idoko; Fatoumata Diallo; Richard A. Adegbola; Yuxiao Tang; Varsha Parulekar; Helen Chadha; Lesley Mabey; Daniel Holme; Kelly Townsend; Julie Chaumont; F. Marc LaForce; Prasad S. Kulkarni; Elisa Marchetti; Simonetta Viviani; Musa Hassan-King; Marie-Pierre Preziosi

ABSTRACT A phase II clinical study was conducted in African toddlers (aged 12 to 23 months), with subjects receiving either investigational meningococcal group A conjugate (PsA-TT), meningococcal ACWY polysaccharide (PsACWY), or Haemophilus influenzae type b (Hib-TT) vaccine. Ten months following vaccination, the 3 study groups were further randomized to receive a dose of PsA-TT, a 1/5 dose of PsACWY, or a dose of Hib-TT vaccine. Group A serum bactericidal antibody (SBA) results have been reported previously, with PsA-TT demonstrating superior immunogenicity versus PsACWY vaccine. Immunogenicity for serogroups W135 and C was assessed by SBA assay to investigate the impact of multiple doses in this age group. Blood samples were taken prior to vaccination, 28 days and 40 weeks post-primary vaccination, and 7 and 28 days post-booster vaccination with a 1/5 dose of PsACWY. Subjects who had previously received a full dose of PsACWY had W135 SBA geometric mean titers (GMTs) of 26.1 and 4.4 at 7 and 28 days post-booster vaccination with a 1/5 PsACWY dose, respectively, whereas the W135 SBA GMTs of naïve subjects at these time points following vaccination with a 1/5 dose of PsACWY were 861.1 and 14.6, respectively. Similar differences were observed for serogroup C, with SBA GMTs of 99 and 5.9 at 7 and 28 days post-booster vaccination with a 1/5 dose of PsACWY, respectively, for naïve subjects, compared to 4.1 and 3.2 for previously vaccinated subjects. Immunologic hyporesponsiveness for groups C and W135 was observed following a full dose of PsACWY vaccine at 12 to 23 months of age and a 1/5 dose of PsACWY 10 months later compared to the case for PsACWY-naïve subjects receiving a 1/5 dose of PsACWY vaccine.


Pediatric Infectious Disease Journal | 1998

A polymerase chain reaction for the diagnosis of Haemophilus influenzae type b disease in children and its evaluation during a vaccine trial.

Musa Hassan-King; Richard A. Adegbola; Ignatius Baldeh; Kim Mulholland; Charles Omosigho; Anslem Oparaugo; Stanley Usen; Ayo Palmer; Gisela Schneider; Ousman Secka; Martin Weber; Brian Greenwood

BACKGROUND Determination of the etiology of pneumonia in young children is difficult because blood culture, the usual method of diagnosis, is positive in only a small proportion of cases. For this reason vaccine trials that include bacterial pneumonia as an endpoint must be large. OBJECTIVES To determine whether a diagnostic test based on a polymerase chain reaction could be used as an alternative to conventional blood culture for diagnosis of invasive Haemophilus influenzae type b (Hib) infections in young children investigated during the course of a large vaccine trial. METHODS DNA was extracted from blood culture supernatants and probed for the presence of Hib DNA with a PCR assay with primers derived from the cap gene locus of Hib. Results of the PCR assay were compared with those obtained by conventional culture techniques. RESULTS Blood cultures were obtained from 1544 children with suspected pneumonia, meningitis or septicemia and from 31 healthy control children who were contacts of cases. Blood culture supernatants were tested for Hib DNA in the PCR test. The sensitivity and specificity of a positive PCR test in blood culture supernatant as against culture of Hib from any normally sterile site were 100 and 99%, respectively. Eleven children had positive Hib PCR tests on blood culture supernatants but were negative by culture. In one of these cases Hib was isolated from a lung aspirate and in two other patients H. influenzae strains other than Hib were obtained from the cerebrospinal fluid. Eight of these 11 children were in the control group. When the results of the PCR assay were used to determine vaccine efficacy, a value of 86% was obtained compared with a figure of 95% obtained when conventional culture techniques were used. CONCLUSIONS An Hib PCR assay on blood culture supernatants proved to be sensitive and specific for the diagnosis of Hib disease in children. The distribution of PCR-positive, culture-negative cases between Hib-vaccinated and control groups paralleled that of culture-positive cases, suggesting that most of these children had been infected with Hib. A trial of a highly efficacious vaccine provides a novel way for evaluating new diagnostic tests for which there is no standard diagnostic test of 100% reliability.


PLOS ONE | 2013

Methods for Identifying Neisseria meningitidis Carriers: A Multi-Center Study in the African Meningitis Belt.

Nicole E. Basta; James M. Stuart; Maria Nascimento; Olivier Manigart; Caroline L. Trotter; Musa Hassan-King; Daniel Chandramohan; Samba O. Sow; Abdoulaye Berthe; Ahmed Bedru; Yenenesh Tekletsion; Jean-Marc Collard; Jean François Jusot; Aldiouma Diallo; Hubert Bassene; Doumagoum Moto Daugla; Khadidja Gamougam; Abraham Hodgson; Abudulai Adams Forgor; Babatunji A. Omotara; Galadima Gadzama; Eleanor R. Watkins; Lisa Rebbetts; Kanny Diallo; Noel S. Weiss; M. Elizabeth Halloran; Martin Maiden; Brian Greenwood

Objective Detection of meningococcal carriers is key to understanding the epidemiology of Neisseria meningitidis, yet no gold standard has been established. Here, we directly compare two methods for collecting pharyngeal swabs to identify meningococcal carriers. Methods We conducted cross-sectional surveys of schoolchildren at multiple sites in Africa to compare swabbing the posterior pharynx behind the uvula (U) to swabbing the posterior pharynx behind the uvula plus one tonsil (T). Swabs were cultured immediately and analyzed using molecular methods. Results One thousand and six paired swab samples collected from schoolchildren in four countries were analyzed. Prevalence of meningococcal carriage was 6.9% (95% CI: 5.4-8.6%) based on the results from both swabs, but the observed prevalence was lower based on one swab type alone. Prevalence based on the T swab or the U swab alone was similar (5.2% (95% CI: 3.8-6.7%) versus 4.9% (95% CI: 3.6-6.4%) respectively (p=0.6)). The concordance between the two methods was 96.3% and the kappa was 0.61 (95% CI: 0.50-0.73), indicating good agreement. Conclusions These two commonly used methods for collecting pharyngeal swabs provide consistent estimates of the prevalence of carriage, but both methods misclassified carriers to some degree, leading to underestimates of the prevalence.


Scandinavian Journal of Infectious Diseases | 1992

DNA Fingerprinting in the Epidemiology of African Serogroup A Neisseria meningitidis

Bjarne Bjorvatn; Musa Hassan-King; Brian Greenwood; Redda Tekle Haimanot; Daniel Fekade; Guy Sperber

The restriction endonuclease (RE) technique was used to compare 172 meningococcal group A strains collected between 1969 and 1990, mainly from countries of the so-called African Meningitis Belt, the Gambia and Ethiopia. The 64 strains from various African countries (Niger, Chad, Burkina Faso, Cameroon, Morocco, Djibouti) were distributed within 3 main restriction enzyme patterns (REPs); the 77 Gambian strains fell into 5 REPs and the 24 Ethiopian strains into 2 such patterns. Several of the main REPs were formed by clusters of closely related clones. Clones, very similar to dominating REPs of the 1960s in Niger, Burkina Faso and Cameroon, were in the 1980s found to be strongly represented in the Gambia to the extreme west of the Meningitis Belt. One of the Gambian clones from 1983-86 was identical to an Indian clone recovered in New Delhi 1986-87. Another clone was detected in 1983 in the Gambia, in 1989 again in the Gambia as well as in Ethiopia, and in 1990 in Tanzania. Our results are largely in line with those of previous studies based on modern techniques of protein and isoenzyme electrophoresis. The RE method is useful mainly for the exact genotypic differentiation of closely related clones, and seems to be a valuable complement to phenotypic tools for epidemiological mapping of Group A meningococcal infection.


The Lancet Global Health | 2016

Household transmission of Neisseria meningitidis in the African meningitis belt: a longitudinal cohort study

Oumer Ali; Abraham Aseffa; Ahmed Bedru Omer; Tsehaynesh Lema; Tesfaye Moti Demissie; Yenenesh Tekletsion; Alemayehu Worku; Haimanot Guebre Xabher; Lawrence Yamuah; Rahamatou Moustapha Boukary; Jean-Marc Collard; Ibrahim Dan Dano; Ibrahim Habiboulaye; Bassira Issaka; Jean-François Jusot; Sani Ousmane; Issoufa Rabe; Doumagoum Moto Dauglaz; Jean Pierre Gami; Kadidja Gamougam; Lodoum Mbainadji; Nathan Naibei; Maxime Narbé; Jacques Toralta; Abdoulaye Berthe; Kanny Diallo; Mahamadou Keita; Adama Coulibaly; Uma Onwuchekwa; Samba O. Sow

BACKGROUND Information on transmission of meningococcal infection in the African meningitis belt is scarce. We aimed to describe transmission patterns of Neisseria meningitidis (meningococcus) in households in the African meningitis belt. METHODS Cross-sectional carriage surveys were done in seven African meningitis belt countries (Chad, Ethiopia, Ghana, Mali, Niger, Nigeria, and Senegal) between Aug 1, 2010, and Oct 15, 2012. Meningococcal carriers identified in these surveys and all available people in their households were recruited into this longitudinal cohort study. We took pharyngeal swabs at first visit and took further swabs twice a month for 2 months and then monthly for a further 4 months. We used conventional bacteriological and molecular techniques to identify and characterise meningococci. We estimated the rates of carriage acquisition and recovery using a multi-state Markov model. FINDINGS Meningococci were isolated from 241 (25%) of 980 members of 133 households in which a carrier had been identified in the cross-sectional survey or at the first household visit. Carriage was detected subsequently in another household member who was not an index carrier in 75 households. Transmission within a household, suggested by detection of a further carrier with the same strain as the index carrier, was found in 52 of these 75 households. Children younger than 5 years were the group that most frequently acquired carriage from other household members. The overall individual acquisition rate was 2·4% (95% CI 1·6-4·0) per month, varying by age and household carriage status. The mean duration of carriage was 3·4 months (95% CI 2·7-4·4). INTERPRETATION In the African meningitis belt, transmission of meningococci within households is important, particularly for young children, and periods of carriage are usually of short duration. FUNDING Bill & Melinda Gates Foundation, Wellcome Trust.


Clinical and Vaccine Immunology | 2014

Development and use of a serum bactericidal assay using pooled human complement to assess responses to a meningococcal group A conjugate vaccine in African toddlers

Margaret C. Bash; Freyja Lynn; Brian Mocca; Ray Borrow; Helen Findlow; Musa Hassan-King; Marie-Pierre Preziosi; Olubukola T. Idoko; Samba O. Sow; Prasad S. Kulkarni; F. Marc LaForce

ABSTRACT A meningococcal group A polysaccharide (PS) conjugate vaccine (PsA-TT) has been developed for African countries affected by epidemic meningitis caused by Neisseria meningitidis. Complement-mediated serum bactericidal antibody (SBA) assays are used to assess protective immune responses to meningococcal vaccination. Human complement (hC′) was used in early studies demonstrating antibody-mediated protection against disease, but it is difficult to obtain and standardize. We developed and evaluated a method for sourcing hC′ and then used the SBA assay with hC′ (hSBA) to measure bactericidal responses to PsA-TT vaccination in 12- to 23-month-old African children. Sera with active complement from 100 unvaccinated blood donors were tested for intrinsic bactericidal activity, SBA titer using rabbit complement (rSBA), and anti-group A PS antibody concentration. Performance criteria and pooling strategies were examined and then verified by comparisons of three independently prepared hC′ lots in two laboratories. hSBA titers of clinical trial sera were then determined using this complement sourcing method. Two different functional antibody tests were necessary for screening hC′. hSBA titers determined using three independent lots of pooled hC′ were within expected assay variation among lots and between laboratories. In African toddlers, PsA-TT elicited higher hSBA titers than meningococcal polysaccharide or Hib vaccines. PsA-TT immunization or PS challenge of PsA-TT-primed subjects resulted in vigorous hSBA memory responses, and titers persisted in boosted groups for over a year. Quantifying SBA using pooled hC′ is feasible and showed that PsA-TT was highly immunogenic in African toddlers.


Transactions of The Royal Society of Tropical Medicine and Hygiene | 2012

Laboratory quality control in a multicentre meningococcal carriage study in Burkina Faso

Paul A. Kristiansen; Abdoul-Salam Ouédraogo; Idrissa Sanou; Absatou Ky Ba; Charles D. Ouédraogo; Lassana Sangaré; Rasmata Ouédraogo; Denis Kandolo; Fabien Diomandé; Pascal Kaboré; Musa Hassan-King; Jennifer Dolan Thomas; Cynthia Hatcher; Ida K. G. Andreasson; Thomas A. Clark; Marie-Pierre Preziosi; Marc LaForce; Dominique A. Caugant

To investigate the potential herd immunity effect of MenAfriVac, a new conjugate vaccine against serogroup A Neisseria meningitidis, a multiple cross-sectional carriage study was conducted in three districts in Burkina Faso in 2009, yielding a total of 20 326 oropharyngeal samples. A major challenge was the harmonisation of operational procedures and ensuring the reliability of results. Here we describe the laboratory quality control (QC) system that was implemented. Laboratory analysis performed by three local laboratories included colony morphology assessment, oxidase test, Gram stain, β-galactosidase activity using o-nitrophenyl-β-galactopyranoside (ONPG), γ-glutamyl transferase (GGT) activity and slide agglutination serogrouping. Internal QC was performed on media, reagents, laboratory equipment and field conditions. Confirmation of results and molecular characterisation was performed at the Norwegian Institute of Public Health (Oslo, Norway). External QC was performed on 3% of specimens where no colonies morphologically resembling N. meningitidis had been identified and on 10% of non-ONPG-/GGT+ isolates. The QC system was a critical element: it identified logistical and operational problems in real time and ensured accuracy of the final data. The overall N. meningitidis carriage prevalence (3.98%) was probably slightly underestimated and the calculated true prevalence was 4.48%. The components of the presented QC system can easily be implemented in any other laboratory study.

Collaboration


Dive into the Musa Hassan-King's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Dominique A. Caugant

Norwegian Institute of Public Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Fabien Diomandé

Centers for Disease Control and Prevention

View shared research outputs
Researchain Logo
Decentralizing Knowledge